Mark L. Jacobson Sells 25,000 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) COO Mark L. Jacobson sold 25,000 shares of Axsome Therapeutics stock in a transaction on Monday, June 9th. The stock was sold at an average price of $110.44, for a total transaction of $2,761,000.00. Following the sale, the chief operating officer now directly owns 5,783 shares in the company, valued at approximately $638,674.52. This trade represents a 81.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Axsome Therapeutics Trading Up 0.0%

Shares of AXSM stock opened at $109.91 on Wednesday. The company’s 50-day moving average price is $105.98 and its 200-day moving average price is $106.83. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. The stock has a market cap of $5.41 billion, a price-to-earnings ratio of -18.35 and a beta of 0.47. Axsome Therapeutics, Inc. has a twelve month low of $64.11 and a twelve month high of $139.13.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Mutual of America Capital Management LLC lifted its holdings in shares of Axsome Therapeutics by 0.3% in the 1st quarter. Mutual of America Capital Management LLC now owns 39,623 shares of the company’s stock worth $4,621,000 after acquiring an additional 136 shares during the last quarter. Pitcairn Co. lifted its holdings in shares of Axsome Therapeutics by 3.4% in the 4th quarter. Pitcairn Co. now owns 4,562 shares of the company’s stock worth $386,000 after acquiring an additional 148 shares during the last quarter. Meridian Wealth Management LLC lifted its holdings in shares of Axsome Therapeutics by 0.7% in the 4th quarter. Meridian Wealth Management LLC now owns 21,171 shares of the company’s stock worth $1,791,000 after acquiring an additional 150 shares during the last quarter. Summit Investment Advisors Inc. lifted its holdings in shares of Axsome Therapeutics by 4.4% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,852 shares of the company’s stock worth $326,000 after acquiring an additional 162 shares during the last quarter. Finally, Arizona State Retirement System lifted its holdings in shares of Axsome Therapeutics by 1.8% in the 4th quarter. Arizona State Retirement System now owns 9,054 shares of the company’s stock worth $766,000 after acquiring an additional 164 shares during the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Analyst Upgrades and Downgrades

AXSM has been the topic of several recent research reports. Mizuho lifted their target price on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the stock an “outperform” rating in a research note on Thursday, March 27th. Bank of America lifted their target price on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the stock a “buy” rating in a research note on Tuesday, February 11th. Cantor Fitzgerald raised shares of Axsome Therapeutics to a “strong-buy” rating in a research note on Wednesday, May 14th. Needham & Company LLC lowered their target price on shares of Axsome Therapeutics from $153.00 to $150.00 and set a “buy” rating on the stock in a research note on Monday. Finally, Jefferies Financial Group initiated coverage on shares of Axsome Therapeutics in a research note on Monday, April 7th. They set a “buy” rating and a $200.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $172.80.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.